Nivolumab plus ipilimumab in non-small-cell lung cancer

被引：43
|
作者：
Reck, Martin [1 ]
Borghaei, Hossein [2 ]
O'Byrne, Kenneth J. [3 ,4 ]
机构：
[1] German Ctr Lung Res, Airway Res Ctr North, LungenClin Grosshansdorf, Woehrendamm 80, D-22927 Grosshansdorf, Germany
[2] Fox Chase Canc Ctr, Dept Hematol Oncol, Div Thorac Med Oncol, 333 Cottman Ave, Philadelphia, PA 19111 USA
[3] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld 4102, Australia
[4] Queensland Univ Technol, Brisbane, Qld 4102, Australia
来源：
FUTURE ONCOLOGY | 2019年 / 15卷 / 19期
关键词：
atezolizumab; CTLA-4; immunotherapy; ipilimumab; nivolumab; non-small-cell lung cancer; pembrolizumab; PD-1; PD-L1; tumor mutational burden; TUMOR MUTATIONAL BURDEN; OPEN-LABEL; PHASE-III; ANTI-PD-1; ANTIBODY; 1ST-LINE TREATMENT; STAGE IV; MAINTENANCE BEVACIZUMAB; CTLA-4; BLOCKADE; SOLID TUMORS; DOCETAXEL;
D O I：
10.2217/fon-2019-0031
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single agents and in combination. In this Review, we examine the potential role of dual immune checkpoint inhibition with nivolumab plus ipilimumab in the management of patients with previously untreated advanced non-small-cell lung cancer, based on results from the Phase III CheckMate 227 study. Immunotherapies with indications in the first-line treatment of non-small-cell lung cancer include pembrolizumab alone and combined with chemotherapy, and atezolizumab combined with bevacizumab and chemotherapy. CheckMate 227 is the first Phase III study evaluating first-line chemotherapy-sparing combination immunotherapy and including tumor mutational burden as a biomarker for patient selection.
引用
收藏
页码：2287 / 2302
页数：16
相关论文
共 50 条
  • [31] Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    Li, Ziming
    Lu, Shun
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1172 - +
  • [32] Nivolumab-induced asthma in a patient with non-small-cell lung cancer
    Maeno, K.
    Fukuda, S.
    Oguri, T.
    Niimi, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (11) : 2891 - 2891
  • [33] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [34] Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
    Provencio, Mariano
    Nadal, Ernest
    Gonzalez-Larriba, Jose L.
    Martinez-Marti, Alex
    Bernabe, Reyes
    Bosch-Barrera, Joaquim
    Casal-Rubio, Joaquin
    Calvo, Virginia
    Insa, Amelia
    Ponce, Santiago
    Reguart, Noemi
    de Castro, Javier
    Mosquera, Joaquin
    Cobo, Manuel
    Aguilar, Andres
    Vivanco, Guillermo Lopez
    Camps, Carlos
    Lopez-Castro, Rafael
    Moran, Teresa
    Barneto, Isidoro
    Rodriguez-Abreu, Delvys
    Serna-Blasco, Roberto
    Benitez, Raquel
    Aguado de la Rosa, Carlos
    Palmero, Ramon
    Hernando-Trancho, Florentino
    Martin-Lopez, Javier
    Cruz-Bermudez, Alberto
    Massuti, Bartomeu
    Romero, Atocha
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (06): : 504 - 513
  • [35] Nivolumab-refractory patients with advanced non-small-cell lung cancer
    Costantini, A.
    Fallet, V.
    Corny, J.
    Friard, S.
    Chouaid, C.
    Duchemann, B.
    Giroux-Leprieur, E.
    Taillade, L.
    Doucet, L.
    Brosseau, S.
    Wislez, M.
    Tredaniel, J.
    Cadranel, J.
    [J]. LUNG CANCER, 2019, 130 : 128 - 134
  • [36] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17): : 1627 - 1639
  • [37] New targeted treatments for non-small-cell lung cancer - role of nivolumab
    Zago, Giulia
    Muller, Mirte
    van den Heuvel, Michel
    Baas, Paul
    [J]. BIOLOGICS-TARGETS & THERAPY, 2016, 10 : 103 - 117
  • [38] Treatment of non-small-cell lung cancer after progression on nivolumab or pembrolizumab
    Freeman, A. T.
    Lesperance, M.
    Wai, E. S.
    Croteau, N. S.
    Fiorino, L.
    Geller, G.
    Brooks, E. G.
    Poonja, Z.
    Fenton, D.
    Irons, S.
    Ksienski, D.
    [J]. CURRENT ONCOLOGY, 2020, 27 (02) : 76 - 82
  • [39] Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
    Ang, Yvonne L. E.
    Lim, Joline S. J.
    Soo, Ross A.
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 3187 - 3195
  • [40] Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient
    Ito, M.
    Fujiwara, S.
    Fujimoto, D.
    Mori, R.
    Yoshimura, H.
    Hata, A.
    Kohara, N.
    Tomii, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (09) : 2318 - 2319
12345